Relevance of ADAMTS13 to liver transplantation and surgery

Saiho Ko, Hisanao Chisuwa, Masanori Matsumoto, Yoshihiro Fujimura, Eiji Okano, Yoshiyuki Nakajima

Saiho Ko, Department of Surgery, Nara Prefecture General Medical Center, Nara 631-0846, Japan
Saiho Ko, Eiji Okano, Yoshiyuki Nakajima, Departement of Surgery, Nara Medical University, Kashihara, Nara 634-8522, Japan
Hisanao Chisuwa, Department of Surgery, Kofu City Hospital, Kofu, Yamanashi 400-0832, Japan
Masanori Matsumoto, Yoshihiro Fujimura, Departement of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara 634-8522, Japan

Author contributions: Nakajima Y conducted entire study; Fujimura Y constructed study design of the analysis of ADAMTS13 and von Willebrand factor related molecules; Matsumoto M instructed the analysis of ADAMTS13 and von Willebrand factor related molecules and refined and improved the entire study; Chisuwa H performed analysis and management of pediatric liver transplant patients; Ko S and Okano E conceived the idea of the study and performed analysis of data, adult liver transplantation, surgery, and management of the patients.

Conflict-of-interest statement: The authors declare no conflict of interest associated with this study.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Saiho Ko, Director, Departement of Surgery, Nara Prefecture General Medical Center, 1-30-1 Hiramatsu, Nara-city, Nara 631-0846, Japan. saiho@naramed-u.ac.jp
Telephone: +81-742-466001
Fax: +81-742-466011

Received: August 24, 2014

Peer-review started: August 24, 2014
First decision: September 16, 2014
Revised: March 23, 2015
Accepted: April 10, 2015
Article in press: April 14, 2015
Published online: July 8, 2015

Abstract
A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) specifically cleaves unusually-large von Willebrand factor (VWF) multimers under high shear stress, and down-regulates VWF function to form platelet thrombi. Deficiency of plasma ADAMTS13 activity induces a life-threatening systemic disease, termed thrombotic microangiopathy (TMA) including thrombotic thrombocytopenic purpura (TTP). Children with advanced biliary cirrhosis due to congenital biliary atresia sometimes showed pathological features of TMA, with a concomitant decrease of plasma ADAMTS13 activity. Disappearance of their clinical findings of TTP after successful liver transplantation suggested that the liver is a major organ producing plasma ADAMTS13. In situ hybridization analysis showed that ADAMTS13 was produced by hepatic stellate cells. Subsequently, it was found that ADADTS13 was not merely responsible to development of TMA and TTP, but also related to some kinds of liver dysfunction after liver transplantation. Ischemia-reperfusion injury and acute rejection in liver transplant recipients were often associated with marked decrease of ADAMTS13 and concomitant formation of unusually large VWF multimers without findings of TMA/TTP. The similar phenomenon was observed also in patients who underwent hepatectomy for liver tumors. Imbalance between ADAMTS13 and VWF in the hepatic sinusoid might cause liver damage due to microcirculatory disturbance. It can be called as “local TTP like mechanism” which plays a crucial role in liver dysfunction after liver transplantation and surgery.
**Key words:** A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13; Thrombocytopenia; Microcirculation; Liver dysfunction; von Willebrand factor; Liver transplantation; Acute rejection; Ischemia-reperfusion injury; Hepatocetomy; Liver surgery; Local thrombotic thrombocytopenic purpura like mechanism

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) is a cleaving protease of von Willebrand factor (VWF). The deficiency of this molecule is known to cause thrombotic thrombocytopenic purpura (TTP). Recent studies revealed that ADAMTS13 might have functional relevance to pathogenesis of various liver disease separately from the development of TTP. Imbalance between ADAMTS13 and VWF in the hepatic sinusoid might cause liver damage due to microcirculatory disturbance. It can be called as "local TTP like mechanism" which plays a crucial role in liver dysfunction after liver transplantation and surgery including ischemia reperfusion injury and acute rejection.

INTRODUCTION

The liver produces a variety of coagulation and fibrinolytic proteins, which are essential to create the hemostatic network on a basis of coagulation cascade. In contrast, plasma von Willebrand factor (VWF) plays a pivotal role in primary hemostasis by anchoring platelets onto the denuded vascular subendothelial matrices under high shear stress generated in microvasculatures. VWF is produced exclusively in vascular endothelial cells as unusually large VWF multimers (UL-VWF) and the secreted into circulation. Before secretion, VWF is cleaved into the smaller multimers by a specific plasma protease, termed a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13), at the peptide bond between Tyr1605 and Met1606 within the VWF-A2 domain. The lack of ADAMTS13 induces excess activity of UL-VWF and may result in microcirculatory disturbance with formation of thrombi in microvasculatures.

The **ADAMTS13** gene is located on chromosome 9q34, and the enzyme consists of 1427 amino acid residues with a multi-domain structure. The initial northern blotting studies indicated that **ADAMTS13** mRNA is exclusively expressed in the liver, and the subsequent immunological studies with in situ hybridization analyses revealed that **ADAMTS13** is unambiguously produced in hepatic stellate cells (Itoh cells). However, **ADAMTS13** was also identified in platelets, vascular endothelial cell, and kidney podocytes. Therefore, an important question has been arisen which organ is most responsible for maintaining the plasma levels of **ADAMTS13** activity. In this regard, we found that pediatric patients with advanced biliary cirrhosis due to bile duct atresia often showed pathological features resembling to thrombotic microangiopathy (TMA) which shows microangiopathic hemolytic anemia, destructive thrombocytopenia, and organ dysfunction caused by platelet thrombi. Further, these patients usually had a significantly low plasma level of **ADAMTS13** activity, and interestingly their clinical and laboratory findings rapidly improved after a successful liver transplantation (our original data). These results strongly suggested that the liver is a major organ producing plasma **ADAMTS13**. In the absence of **ADAMTS13**, UL-VWF released from vascular endothelial cells left uncleaved, which induce platelet hyperagglutination under high shear stress and generate platelet thrombi in organ microcirculation typically shown in thrombotic thrombocytopenic purpura (TTP), a life-threatening generalized disease and a phenotype of common pathological features of TMA.

Subsequently we have reported that the decrease of plasma **ADAMTS13** activity correlates with the disease progression of various chronic liver diseases including hepatitis C-associated liver cirrhosis, the ischemia-reperfusion injury and acute rejection in liver transplant recipients, and hepatic dysfunction after hepatectomy for liver tumors. The hepatic sinusoid is the narrowest vascular structure within the liver and is the principal site of blood flow regulation. The anatomical location of hepatic stellate cells, which embrace the sinusoids, provides a favorable arrangement for sinusoidal constriction, and for control of sinusoidal vascular tone and blood flow. Because of this specific microanatomical environment, it is suspected that hepatic stellate cell is a key player in regulating hepatic sinusoidal blood circulation. From this point of view, this review is showing the dynamics of **ADAMTS13** activity and its clinical relevance to the pathogenesis of liver dysfunction after liver transplantation and surgery.

ENDOTHELIAL CELL INJURY AND **ADAMTS13** IN CIRRHOTIC LIVER

The mechanism of thrombocytopenia in patients with liver cirrhosis provides suggestion to relevance of **ADAMTS13** to development of liver dysfunction due to microcirculatory disturbance. It has been speculated that thrombocytopenia in liver cirrhosis is caused by hypersplenism and impaired synthesis of thrombopoietin in the liver. However, **Uemura et al** provided an evidence of increase of UL-VWF in patients with severe liver cirrhosis. Thrombocytopenia may be enhanced by platelet aggregation increased UL-VWF.
under high shear stress. Their data showed a significant reduction of plasma ADAMTS13 activity in patients with advanced liver cirrhosis mainly caused by hepatitis C virus infection[20]. The results are consistent with reports by Mannucci et al[21] and Feys et al[22]. Severity of decreased ADAMTS13 activity was parallel to impaired hepatic functional reserve[20]. The plasma ADAMTS13 activity in Child-Pugh classification (Child) C patients was significantly lower than those in patients with Child A and B. Among these, UL-VWFM-positive patients showed the lowest plasma ADAMTS13 activity, most impaired liver and renal function, and lowest Child-Pugh scores. These results indicate that severe cirrhosis may be prone to platelet aggregation. High susceptibility to thrombotic formation may be supported by high incidence of portal or hepatic venous thrombosis in patients with severe liver cirrhosis[23,24]. Even in the absence of clinically overt thrombotic events, microcirculation may be disturbed by formation of platelet microthrombi caused by the enzyme-substrate imbalance between ADAMTS13 and UL-VWFM.

Substantial increase of plasma VWF levels according to progression of liver diseases has been reported previously[25,26]. This is probably due to endothelial damage of the hepatic sinusoid caused by endotoxin and cytokines[25-28]. Hepatic cell necrosis and subsequent liver regeneration, and/or high shear stress due to portal hypertension in cirrhotic liver may play major roles in up-regulating VWF in hepatic sinusoidal endothelium. The mechanism responsible for the decrease of ADAMTS13 activity in advanced cirrhotic patients may include enhanced consumption due to a degradation of a large quantities of VWF[21], inflammatory cytokines[29,30], and/or ADAMTS13 plasma inhibitor[13,31]. These findings in patients with liver cirrhosis suggest that imbalance between ADAMTS13 and UL-VWFM can induce liver dysfunction due to microcirculatory disturbance.

It is well-known that ticlopidine, which is one of the most popular antiplatelet agents, can be a cause of severe deficiency of ADAMTS13 activity, the condition known as TTP[32]. The drug may induce inhibitor of ADAMTS13. Because the patients with cirrhosis are prone to deficiency of ADAMTS13 activity, the use of ticlopidine is better to be avoided as possible.

ASSAY SYSTEM OF ADAMTS13 AND UL-VWFM

The article contains some original data in the part of liver transplantation and surgery. ADAMTS13 and UL-VWFM were measured with the methods described below. Written informed consent was obtained in all patients in whom the blood samples were used for the assay.

Traditionally, the activity of plasma ADAMTS13 was measured by the multimer method using full length VWF as a substrate according to the method reported by Furlan et al[12], although we made slight modification to this method as described in our previous study[15]. The method required at least 3 d to assay the activity of ADAMTS13. Our newly developed method is enzyme-linked immunosorbent assay (ELISA) using a specific murine monoclonal antibody to Tyr1605 residue of VWF-A2 domain which is generated by ADAMTS13 cleavage. Recombinant GST-VWF73-His polypeptide is used as a substrate[33]. One of the advantages of this method is that the assay time is significantly shortened. This new method is more sensitive and more rapid than the traditional multimer method. This ELISA kit is available on commercial base now. Plasma UL-VWFM can be analyzed by vertical agarose gel electrophoresis as described[16].

IMPACT OF ADAMTS13 IN PATIENTS WITH LIVER TRANSPLANTATION

We have revealed significant decrease of ADAMTS13 activity in very sick children with advanced cirrhotic biliary atresia (BA) and full recovery of the activity after living-related liver transplantation (LRLT). This finding strongly suggested that the liver is the major source of ADAMTS13. Briefly, 8 pediatric patients with BA received LRLT from adult live donors, indicating that almost a normal size of liver was transplanted into the recipients (Table 1). Before LRLT, plasma ADAMTS13 activity showed a significant decrease in 7 out of 8 patients, and the value for two patients (cases 1 and 8) was extremely low at 13% and 6% of the control, respectively. One to three months after successful LRLT, six patients showed an increase in ADAMTS13 activity. It is noteworthy that decreased ADAMTS13 activity restored by liver transplantation in the majority of patients (Figure 1). Table 1 and Figure 1 are original data of our research team. With regard to the increase in ADAMTS13 activity after LRLT, there were two possible explanations. One is simply that the liver is the major organ to synthesize ADAMTS13, like blood coagulation factors VIII and IX previously shown in hemophiliacs who received liver transplantation[34-36]. Another explanation might be that liver dysfunction produces a harmful substance which may affect the systemic production or activity of ADAMTS13. However, the presence of a substance interfering with the enzyme activity is plausible, because no inhibitor of ADAMTS13 was detected in sick BA patients. While the site of ADAMTS13 synthesis still remained to be elucidated at the time of study about pediatric BA patients, the results strongly suggested that the liver is the critical organ in the synthesis of ADAMTS13. Following this finding, our research group performed in situ hybridization analyses of the liver, which revealed that stellate cells (Ito cells) of sinusoid of the liver produced ADAMTS13[7].

Subsequently, we experienced one noticeable adult patient who developed severe thrombocytopenia soon after LRLT because of advanced liver failure due to Budd-Chiari syndrome (Figure 2). The analysis of the thrombocytopenic mechanism in this patient gave a
Table 1 Profiles of patients who received living-related liver transplantation

| Case | Age | Sex | Underlying disease | ABO-Rh (D) blood group | SV (g) | Presence of schistocytes before LRLT | Relation to the donor | Age | ABO-Rh(D) blood group | GV (g) | GV/SV ratio |
|------|-----|-----|-------------------|-----------------------|-------|-------------------------------------|----------------------|-----|---------------------|-------|------------|
| 1    | 9 mo| M   | BA                | A+                    | 274   | +                                   | Father               | 35 yr| A+                  | 290   | 1.06       |
| 2    | 1 yr 4 mo | F | BA | A+ | 245   | + | Mother | 38 yr | A+ | 314 | 1.28 |
| 3    | 12 yr| F   | BA    | A+       | 891   | -    | Mother | 44 yr | A+ | 392 | 0.44 |
| 4    | 11 mo| F   | BA    | A+       | 259   | +    | Mother | 35 yr | A+ | 306 | 1.18 |
| 5    | 8 mo | F   | BA    | A+       | 185   | +    | Father | 36 yr | O+ | 263 | 1.42 |
| 6    | 1 yr | F   | BA    | A+       | 262   | +    | Mother | 41 yr | O+ | 215 | 0.82 |
| 7    | 11 mo| F   | BA    | AB+      | 280   | -    | Mother | 35 yr | A+ | 266 | 0.95 |
| 8    | 7 mo | M   | BA    | A+       | 226   | -    | Mother | 30 yr | A+ | 228 | 1.01 |

LRLT: Living-related liver transplantation; SV: Standard liver volume; GV: Graft liver volume; BA: Biliary atresia; M: Male; F: Female.

Figure 1 Plasma a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 activity before and after living-related liver transplantation. Predominantly decreased ADAMTS13 activity could be fully restored after living-related liver transplantation in 6 out of 8 sick children with advanced cirhotic biliary atresia (cases 1, 4, 5, 6, 7 and 8). Pre: Before transplantation; LRLT: Living-related liver transplantation; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13.

paradigm shift, which closely linked the axis of VWF-ADAMTS13 reaction to liver transplantation. Briefly, during his uneventful clinical course in the early stage after liver transplantation, the platelet count decreased gradually from 83000/μL to 62000/μL until postoperative day 5, and decreased further to 25000/μL until day 7 (Figure 2, left). While the patient developed graft liver dysfunction due to acute rejection around day 7, no possible causes of thrombocytopenia were found from clinical findings and usual laboratory tests. To make a decision of platelet transfusion to this patient, plasma ADAMTS13 activity was assessed. This was because it has been said that prophylactic platelet transfusion is better avoided to TMA-patients, who had no manifestations of overt bleeding[37]. The result of assay showed a remarkable decrease of ADAMTS13 activity to 3% from 108% before surgery. Presence of UL-VWF in patient plasma was also identified apparently on day 1 and day 7 using SDS-agarose gel electrophoretic analysis (Figure 2, right panel). Transfusion of a large amount of fresh frozen plasma (FFP) as a treatment for TMA together with a high-dose steroid pulse therapy as treatment for acute rejection resulted in recovery of thrombocytopenia and liver function, and substantial increase of ADAMTS13. Thereafter, the ADAMTS13 activity finally recovered to 50%, corresponding to the lower limit of the normal range, until day 98. The UL-VWF tended to diminish on day 15, but again became prominent on day 22 during the second episode of acute rejection, and became undetectable until day 45. Profound decrease of plasma ADAMTS13 is a specific finding of TMA which is known as a sporadic serious complication after solid organ transplantation with an estimated frequency of 0.5%-3.0%[38-41]. However, the patient never showed any apparent clinical features including renal dysfunction, neuro-psychological symptoms or hemolytic anemia, as typically seen in TMA[41]. Because the patient certainly had a remarkably increased plasma level of VWF, together with the presence of UL-VWF, we have supposed that platelet transfusion might generate microcirculatory disturbance due to the enhanced microthrombi formation, initially localized to the transplant liver, but later could be expanded systematically. This idea came from the findings, in which liver transplantation often accompanies with the endothelial cell damage due to ischemia-reperfusion injury and acute rejection. In fact, the injured hepatic vascular endothelial cells may release a large quantity of VWF/UL-VWF,[42-43], which may induce a consumption of ADAMTS13 in plasma. Then we supposed new hypothesis that the initiation of pathological mechanism may occurs locally at the site of the transplanted liver.

Based on these findings, we have started analysis of ADAMTS13 activity and UL-VWF in patients after liver transplant recipients. The results revealed that significant decrease of ADAMTS13 and up-regulation of UL-VWF were commonly and frequently observed after liver transplantation without findings of usual systemic TMA or TTP[15]. These changes in ADAMTS13 activity and UL-VWF were relevant to posttransplant liver dysfunction, including ischemia-reperfusion injury and acute rejection (Figure 3). Many of patients with decreased ADAMTS13 activity showed concurrent thrombocytopenia. The clinical manifestation was analogous with TMA, especially to TTP. However, different from TTP, the deterioration was restricted to the transplanted liver, without development
of renal dysfunction or neurological disorders which were characteristic to usual TTP. Then we have advocated “local TTP like mechanism” for the first time as a pathogenesis of imbalance between plasma ADAMTS13 and UL-VWF in liver transplant recipients\cite{15}.

It was reported that increased numbers of activated platelets and VWF expression were indicated in the hepatic sinusoidal endothelial cells of the re-perfused or cold-preserved liver\cite{42,43}. VWF expression was increased significantly in the grafted liver with acute rejection due to allogenic immune response\cite{43}. After up-regulation of VWF, formation of UL-VWF on the vascular endothelial cells may induce platelet thrombi in the hepatic sinusoid. This may be the mechanism of microcirculatory disturbance due to imbalance between ADAMTS13 and UL-VWF in liver transplant recipients. This hypothesis explains clearly why organ dysfunction restricts to the grafted liver in liver transplant recipients with low ADAMTS13 activity, distinct from systemic organ disorders in patients with “classical TTP”.

Recent report by Kobayashi et al\cite{44} confirmed our findings by showing cross correlation between decrease of ADAMTS13 activity and thrombocytopenia in 81 liver transplant recipients. They also showed increased levels of VWF and up-regulated UL-VWF. More recently, Hori et al\cite{45} reported poor outcomes in patients who developed TMA like disorder after liver transplantation. Most of these patients showed marked decrease of ADAMTS13 activity, while they did not include ADAMTS13 activity in the diagnostic criteria of the disorder. Cross correlation between low ADAMTS13 activity and poor outcomes of the patients was shown in their study.

Following our study\cite{15}, another group also reported that a reduction of ADAMTS13 activity after liver transplantation\cite{46}. They insisted that reduction of ADAMTS13 correlated to thrombotic complication by showing a patient with hepatic artery thrombosis. However, different from our findings, they failed to detect UL-VWF in any...
Ko S et al. ADAMTS13 in liver transplantation and surgery

Figure 3 A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 activity before and after treatment for acute rejection in a liver transplant recipient. Decreased ADAMTS13 activity during acute rejection recovered after treatment for rejection. Pre: Before transplantation; FFP: Fresh frozen plasma; ALT: Alanine transaminase; LDH: Lactate dehydrogenase; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13.

patients with decreased ADAMTS13 activity. The authors speculated that increased plasmin or other proteolytic enzymes cleaved UL-VWFM demonstrating increased plasma levels of tissue plasminogen activator in these patients[46,47]. However, if plasmin cleaves UL-VWFM effectively, thrombotic complications could be prevented. Actually, it has been accepted commonly that UL-VWFM is detected in patients with TTP[20,48]. This may suggest that the deficiency of ADAMTS13 can induce formation of UL-VWFM independently of plasmin and other proteolytic pathways. In addition, hepatic artery thrombosis is a complication crossly linked technical and anatomical implications at the arterial anastomotic site. Basically, ADAMTS13 relates to the formation of platelet thrombi at the "micro" vasculature. Thrombosis of peripheral arterial system as a consequence of microcirculatory disturbance of the graft liver and surgical hepatic arterial thrombosis at the anastomotic site should be distinguished strictly to elucidate the real correlation between ADAMTS13 and the development of thrombotic complications after liver transplantation.

Our experience in liver transplant recipients strongly emphasize the importance of monitoring plasma ADAMTS13 activity not only in diagnosing adverse events including ischemic injury and acute rejection, but also in the treatment of thrombocytopenia after liver transplantation. It should be stressed that platelet transfusion under the decreased activity of ADAMTS13 in liver transplant recipients may deteriorate graft microcirculatory disturbance due to further formation of platelet aggregates in the liver via the "local TTP" mechanism[15]. Liver dysfunction with marked decrease of ADAMTS13 activity should be treated with a large amount of FFP or plasma exchange as indicated for TTP, even when the patient shows no clinical signs of usual TTP.

**KINETICS OF ADAMTS13 AFTER HEPATECTOMY FOR LIVER TUMORS**

Hepatectomy is mainly indicated for treatment of liver tumors. Because hepatic functional mass is reduced after hepatectomy, thrombo-hemostasis related agents produced in the liver may decrease at least in the early phase before regeneration of the residual liver. Because ADAMTS13 is produced mainly by the hepatic stellate cells[7], production of ADAMTS13 may decrease after hepatectomy. In addition, ischemia-reperfusion injury of the liver is an inevitable event in liver surgery due to manipulation of the liver and/or Pringle's maneuver which occludes hepatic blood inflow transiently to decrease bleeding during hepatic transection[49]. Therefore, hepatectomy may induce UL-VWFM in the hepatic sinusoid and result in microcirculatory disturbance via the "local TTP like mechanism" as mentioned in the liver transplantation section. Liver failure is a most serious complication after liver surgery. Microcirculatory disturbance may further deteriorate liver dysfunction after hepatectomy.

We reported that plasma ADAMTS13 decreased significantly after hepatectomy[16]. The activity of ADAMTS13 showed marked and rapid drop from 67% ± 30.6% before surgery to 48% ± 24.6% (mean ± standard deviation) on day 1 after hepatectomy (n = 70, P < 0.0001)[16]. The decrease of ADAMTS13 activity was more profound in patients with major hepatectomy in comparison to those with minor hepatectomy[16]. Multivariate analysis revealed that patients with Pringle's maneuver for longer than 60 min induced most marked decrease of ADAMTS13 activity compared to those with shorter Pringle's maneuver and those without Pringle's maneuver (Figure 4). The severity of ADAMTS13 reduction was significantly correlated with the amount of resected liver mass and the severity of ischemic injury of the liver. ADAMTS13 activity on day 1 strongly correlated with the postoperative maximal levels of total bilirubin as an indicator of postoperative liver dysfunction[16]. These results suggested crucial roles of ADAMTS13 in liver dysfunction and liver failure after hepatectomy.

Figure 5 shows kinetics of ADAMTS13 and UL-VWFM in a patient who underwent major hepatectomy with long Pringle's maneuver. Interestingly, ADAMTS13 activity did not decrease during ischemia by Pringle's maneuver, and decreased very significantly after re-perfusion until the next day. UL-VWFM did not appear during ischemia, and significantly up-regulated after surgery. Induction of UL-VWFM and decrease of ADAMTS13 may develop in the reperfusion phase after ischemic events.
Marked decrease of platelet count with unexplainable origin is often observed during the first postoperative week after hepatectomy. In our study, significant correlation was observed between ADAMTS13 activity and decrease of platelet count. Reduction of ADAMTS13 synthesis by decreased hepatic functional mass after hepatectomy may be a cause of decreased plasma ADAMTS13 activity. Another possible mechanism of marked decrease of ADAMTS13 may be high shear stress after major hepatectomy. Major hepatectomy increases relative amount of portal inflow of residual liver. Because UL-VWFM is stretched by high shear stress, a large amount of ADAMTS13 may be consumed. Decrease of ADAMTS13 may be a possible indicator of postoperative liver dysfunction. From our findings, 40% may be the safe line of ADAMTS13 activity after hepatectomy. Replacement therapy for decreased ADAMTS after hepatectomy is needed to be further elucidated.

THROMBOCYTOPENIA AND TRANSFUSION OF PLATELET CONCENTRATES

Various degrees of thrombocytopenia are commonly observed in cirrhotic patients and in those who received surgical interventions, such as liver transplantation and hepatectomy. Before discovery of ADAMTS13, transfusion of platelet concentrates to these patients has been simply and routinely performed to prevent hemorrhagic events. But after discovery of ADAMTS13, the investigators have become cautious to platelet transfusions to such patients. This is because our groups of investigators have shown that a significant decrease of plasma ADAMTS13 activity and vice versa a remarkably high plasma concentration of VWF, containing UL-VWFM, are both frequently observed in patients with various liver diseases including surgical interventions. These circumstances generate an extremely high plasma ratio of VWF or UL-VWFM to ADAMTS13, that lead to an unstable condition forming platelet thrombi by UL-VWFM.
under high shear stress generated in microvasculatures, and may induce multiple organ failure resembling to TTP. Actually, porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency due to platelet aggregation in microcirculation of the liver and lung, and the pulmonary arterial pressure fell after replacement of plasma ADAMTS13 by infusion of FFP [54]. Thus, our opinion is that the measurement of plasma ADAMTS13 activity is pre-requisite during the clinical course in these patients, and the prophylactic platelet infusion is better to be avoided or rather contraindicated. However, we also must emphasize that platelet transfusions should be performed if overt bleeding once developed, supplying ADAMTS13 by infusion of FFP simultaneously.

CONCLUSION

ADAMTS13/UL-VWF paradigm, which we advocated, is a new concept in the field of liver disease and surgery. The partnership between hematology and hepatology not only suggests a novel mechanism for thrombocytopenia, but also provides a useful diagnostic tool for the treatment of thrombocytopenia and liver dysfunction in patients with various liver diseases. Introduction of ADAMTS13 activity assay system as a routine clinical laboratory tests may help to prevent inadequate platelet transfusion. The efficacy of preemptive supplementation of ADAMTS13 activity by administrating FFP as a source of ADAMTS13 after liver surgery should be investigated in view of ADAMTS13/UL-VWF dynamics. We are particularly interested in developing recombinant ADAMTS13 preparations, which provides a new therapy for patients with hematologic and various liver diseases.

ACKNOWLEDGMENTS

The late Professor Masahiro Uemura, Third Department of Internal Medicine, Nara Medical University Hospital who provided many useful ideas and advices especially on the topic of correlation between ADAMTS13 and chronic liver disease contributed significantly to this article. We sincerely remark that Professor Masahito Uemura was an extraordinary excellent hepatologist, deceased before the completion of the manuscript.

REFERENCES

1 Kujovich JL. Hemostatic defects in end stage liver disease. Crit
Care Clin 2005; 21: 563-587 [PMID: 15992673 DOI: 10.1016/j.jccc.2005.03.002]

Northrup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, Houghten MR, Ikura Y, Caldwell SH. Coagulation in Liver Disease Group: Hypercoagulability and thrombophilia in liver disease. J Thromb Haemost 2008; 6: 2-9 [PMID: 17892532 DOI: 10.1111/j.1538-7836.2007.02727.x]

Mojave JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600 [PMID: 12192020 DOI: 10.1056/NEJMra020528]

Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor:cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002; 75: 25-54 [PMID: 11843266 DOI: 10.1080/02821079.2002.11324340]

Plairnauer B, Zimmermann K, Völk D, Antoine G, Kerschbaumer R, Jena P, Furlan M, Gerson L, Schwarzwald B, Schwarz HP, Schefflinger F. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 160: 3626-3632 [PMID: 12393399 DOI: 10.1182/blood.2002-05-1397]

Sooejima K, Minami N, Hiroshima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001; 130: 475-480 [PMID: 11574066 DOI: 10.1093/oxfordjournals.jbchem.a003009]

Uemura M, Tatsumi K, Matsumoto M, Fujimura M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y. Localization of ADAMTS13 to the stellate cells of human liver. Biochim Biophys Acta 2005; 10: 922-924 [PMID: 15585520]

Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, Shibano T, Ashida S, Sooejima K, Okada Y, Ikeda Y. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biophys Biochem Biophys 2004; 313: 212-216 [PMID: 14672719 DOI: 10.1016/j.bibb.2003.11.111]

Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 2009; 14: 5102-5111 [PMID: 19822897 DOI: 10.1182/blood-2009-07-231597]

Manea M, Kristoffersson A, Schneppenheim R, Saleem MA, Mathieson PW, Mögelin M, Björk P, Holmberg L, Karpman D. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2005; 10: 651-662 [PMID: 17627784 DOI: 10.1111/j.1365-2457.2007.06694.x]

Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, Mcgee BM, Yang AX, Siemianik DR, Stark KR, Gruppo R, Amitrano L, Cao WJ, Albornoz L, Patricelli R, Mannucci PM. ADAMTS13 activity to antigen ratio in healthy young people with physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 10: 534-540 [PMID: 17608762 DOI: 10.1111/j.1365-2457.2007.06688.x]

Albornoz L, Alvarez D, Otaso JC, Kodama A, Sanyal AJ, Anstee QM, Hoffman MR, Ikura Y, Caldwell SH. ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. J Hepatocell Carcinoma 2010; 43: 1780-1786 [PMID: 19998929 DOI: 10.1111/j.1365-2457.2007.06688.x]

Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001; 21: 337-349 [PMID: 11586404 DOI: 10.1053/sliver.2001-17551]

Ester RH. Probing of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45: 645-657 [PMID: 5327481 DOI: 10.1172/JCI105380]

Peck-Radosavljevic M, Wichtas M, Zacherl J, Stiegler G, Stahlwitz P, Fuchsóger K, Keil A, Metz-Schimmel SP, Panzer S, Steininger R, Mühbacher F, Ferenc P, Pillich J, Gangl A. Thrombopoiesis induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795-801 [PMID: 10648388]

Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka S, Yoshihji H, Tsujimoto T, Kurumata N, Fukui K. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2009; 98: 1019-1029 [PMID: 18521503 DOI: 10.1160/TH08-01-0006]

Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735 [PMID: 11675345]

Feyts HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorebeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 10: 534-540 [PMID: 17608762 DOI: 10.1111/j.1365-2457.2007.06688.x]

Amirzadeh MA, Branacccio VV, Margagnone M, Manguo F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741 [PMID: 15094219 DOI: 10.1016/j.jhep.2004.01.001]

Wallen IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247 [PMID: 7773629 DOI: 10.1002/hep.1820910115]

Schrorer AE, Moldof CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells: an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30: 451-455 [PMID: 10190728 DOI: 10.1016/S0168-8278(99)01044-1]

Ferro D, Quinzarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Viole AM. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-1383 [PMID: 8675154 DOI: 10.1002/hep.5102306163]

Cao WJ, Shang DZ, Zheng XL. Inflammatory cytokines modulate von Willebrand factor expression in human umbilical vein endothelial cells. Thromb Haemost 2004; 91: 100-106 [PMID: 15026315]
Von Willebrand factor--cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Blood 1999; 94: 2870-2875 [PMID: 1038673 DOI: 10.1182/blood.1999070578]

Scharrer I, Hambley H, Williams R. Liver transplantation for haemophiliacs in the 2000s. Blood Rev 2010; 24: 185-191 [PMID: 20472107 DOI: 10.1016/j.blre.2010.05.003]

Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005; 42: 420-421 [PMID: 15710227 DOI: 10.1016/j.jhep.2004.08.030]

Belghiti J, Noun R, Zante E, Ballet T, Sauvaget A. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg 1996; 224: 155-161 [PMID: 8757378]

Kobayashi S, Yokoyama Y, Matsushita T, Kainuma M, Ebata T, Igami T, Sugawara G, Takahashi Y, Nagino M. Increased von Willebrand Factor to ADAMTS13 balance during orthotopic liver transplantation. Am J Transplant 2009; 9: 1189-1196 [PMID: 19422343 DOI: 10.1111/j.1600-6143.2009.02621.x]

Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878-885 [PMID: 20406681 DOI: 10.1182/blood-2010-02-261891]

Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005; 42: 420-421 [PMID: 15710227 DOI: 10.1016/j.jhep.2004.08.030]

Belghiti J, Noun R, Zante E, Ballet T, Sauvaget A. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg 1996; 224: 155-161 [PMID: 8757378]

Kobayashi S, Yokoyama Y, Matsushita T, Kainuma M, Ebata T, Igami T, Sugawara G, Takahashi Y, Nagino M. Increased von Willebrand Factor to ADAMTS13 ratio as a predictor of thrombotic microangiopathy. J Hepatol 2010; 52: 909-917 [PMID: 20317828 DOI: 10.1016/j.jhep.2009.11.002]

Melloul E, Dondéro F, Vilgrain V, Raptis DA, Paugam-Burtz C, Belghiti J. Pulmonary embolism after elective liver resection: a prospective analysis of risk factors. J Hepatol 2012; 57: 1268-1275 [PMID: 22889956 DOI: 10.1016/j.jhep.2012.08.004]

Chatzipetrou MA, Tsaroucha AK, Weppler D, Pappas PA, Kenyon NS, Nery JR, Khan MF, Kato T, Pinna AD, O'Brien C, Viciana A, Ricordi C, Tzakis AG. Thrombocytopenia after liver transplantation. Transplantation 1999; 68: 932-938 [PMID: 10610159 DOI: 10.1097/00007890-199904220-00004]

Ben Hamida C, Lautzet JY, Rézaiguida-Delcœux S, Duvoux C, Cherqui D, Duvaldestin P, Stéphan F. Effect of severe thrombocytopenia on patient outcome after liver transplantation. Intensive Care Med 2009; 35: 827-830 [PMID: 23149063 DOI: 10.1007/s00134-011-2477-3]

P. Reviewer: Ikura Y, Makishima M, Poltronieri P; S-Editor: Gong XM; L-Editor: A; E-Editor: Liu SQ
